Literature DB >> 9042652

Diagnostic principles in pleural disease.

R W Light1.   

Abstract

When a patient with an undiagnosed pleural effusion is evaluated, the first question to answer is whether the patient has a transudate or an exudate. This is best done using Light's criteria, but these criteria occasionally misidentify a transudate as an exudate. If the patient's pleural fluid meets exudative criteria, but the patient appears clinically to have a transudative effusion, then the serum-pleural fluid albumin gradient should be measured. If this is greater than 1.2 g-dL-1, the patient probably does have a transudative effusion. If the patient has an exudative pleural effusion, additional tests are indicated to determine the aetiology of the effusion. The gross appearance and the odour of the pleural fluid should be noted and samples of all exudates should be sent for bacterial cultures. Laboratory tests that are useful in the differential diagnosis of exudative pleural effusions include: differential white cell count of the pleural fluid; cytology of the pleural fluid; and levels of adenosine deaminase, glucose, amylase and lactate dehydrogenase in the pleural fluid. If pleural tuberculosis is suspected, a needle biopsy of the pleura is indicated. Thoracoscopy is very efficient at diagnosing malignant pleural effusion and tuberculosis pleuritis, but rarely establishes any other diagnosis.

Entities:  

Mesh:

Year:  1997        PMID: 9042652     DOI: 10.1183/09031936.97.10020476

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  29 in total

Review 1.  Inhaled transmembrane ion transport modulators and non-steroidal anti-inflammatory drugs in asthma.

Authors:  S Bianco; M Robuschi; A Vaghi; A Fumagalli; P Sestini
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

2.  BTS guidelines for the investigation of a unilateral pleural effusion in adults.

Authors:  N A Maskell; R J A Butland
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

3.  Paradigms in the management of hepatic hydrothorax: past, present, and future.

Authors:  Sachin Kumar; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2012-09-25       Impact factor: 6.047

4.  In-depth proteomic analysis of six types of exudative pleural effusions for nonsmall cell lung cancer biomarker discovery.

Authors:  Pei-Jun Liu; Chi-De Chen; Chih-Liang Wang; Yi-Cheng Wu; Chia-Wei Hsu; Chien-Wei Lee; Lien-Hung Huang; Jau-Song Yu; Yu-Sun Chang; Chih-Ching Wu; Chia-Jung Yu
Journal:  Mol Cell Proteomics       Date:  2015-01-31       Impact factor: 5.911

5.  A potential role for VEGF in the diagnostic approach of pleural effusions.

Authors:  Aggeliki Psatha; Demosthenes Makris; Theodora Kerenidi; Zoe Daniil; Theodoros Kiropoulos; Konstantinos Gourgoulianis
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

Review 6.  Medical thoracoscopy in China-the present status and the future.

Authors:  Jing-Yuan Liu; Liang Xiong; Min Zhang; Shi-Yuan Shuai; Xiao-Shan Wei; Lin-Lin Ye; Qiong Zhou
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

Review 7.  A review of the management of complex para-pneumonic effusion in adults.

Authors:  Vikas Koppurapu; Nikhil Meena
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

Review 8.  Clinical practice: treatment of childhood empyema.

Authors:  Marijke Proesmans; Kris De Boeck
Journal:  Eur J Pediatr       Date:  2009-02-24       Impact factor: 3.183

9.  Matrix metalloproteinases production in malignant pleural effusions after talc pleurodesis.

Authors:  P D'Agostino; A Rao Camemi; R Caruso; F Arcoleo; A Cascio; A Dolce; E Sacco; G Cangemi; T di Rosa; P Moceo; E Cillari
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

10.  Diagnostic and predictive role of cell-free midkine in malignant pleural effusions.

Authors:  Mingming Lv; Yongbin Mou; Ping Wang; Yueqiu Chen; Tingting Wang; Yayi Hou
Journal:  J Cancer Res Clin Oncol       Date:  2012-12-05       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.